SVP, Head of Regulatory and R&D and Commercial Quality
Alexion Pharmaceuticals Inc.
Martine Zimmermann is Senior Vice President and Head of Regulatory Affairs, R&D & Commercial Quality at Alexion, AstraZeneca Rare Disease. Dr Zimmermann has over 28 years of combined R&D and global regulatory strategy experience. She joined Alexion in 2009 and has since then been dedicated to the registration of several orphan medicinal products across the globe, as well as to the shaping of the regulatory environment for medicines under development for rare diseases. Throughout her career, Martine has been directly involved in multiple regulatory approvals across the globe and most recently ULTOMIRIS approval in the U.S. for generalized myasthenia gravis in May 2022. Prior to Alexion, Dr Zimmermann held numerous R&D and regulatory roles in companies such as Aventis (now Sanofi), Servier and H. Lundbeck A/S. Dr Zimmermann also serves currently as a Director in the Board of Inventiva Pharma. Dr. Zimmerman received her Pharm.D. from University Louis Pasteur in Strasbourg (France).
Disclosure information not submitted.
Monday, September 12, 2022
9:45 AM – 11:00 AM MST
Tuesday, September 13, 2022
9:45 AM – 11:00 AM MST